"The results for efsitora show it is as effective as existing insulin alternatives in controlling blood sugar, lasting for a week instead of just a day."
"Dr. Athena Philis-Tsimikas highlighted that for those needing supplementary insulin, the change to efsitora could significantly improve their management of type 2 diabetes."
At the American Diabetes Association's 85th Scientific Sessions, Dr. Athena Philis-Tsimikas presented promising Phase 3 results for efsitora alpha, a long-lasting insulin from Eli Lilly. This new insulin shows similar effectiveness to existing options like Novo Nordisk's Awiqli but lasts in the body for a week. This advancement is particularly impactful for 20-30% of type 2 diabetes patients requiring supplementary insulin, as it may simplify treatment by reducing the frequency of injections needed for blood sugar management.
Read at www.mercurynews.com
Unable to calculate read time
Collection
[
|
...
]